• Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
    Apr 20 2026

    Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.

    CME information and select publications here.

    Show More Show Less
    59 mins
  • CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
    Apr 10 2026

    Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

    CME information and select publications here.

    Show More Show Less
    25 mins
  • Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
    Apr 1 2026

    Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

    CME information and select publications here.

    Show More Show Less
    25 mins
  • CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
    Mar 23 2026

    Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

    CME information and select publications here.

    Show More Show Less
    24 mins
  • Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
    Mar 21 2026

    Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

    CME information and select publications here.

    Show More Show Less
    29 mins
  • CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
    Mar 13 2026

    Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.

    CME information and select publications here.

    Show More Show Less
    1 hr and 3 mins
  • Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting
    Mar 11 2026

    Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.

    CME information and select publications here.

    Show More Show Less
    47 mins
  • Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
    Mar 9 2026

    Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

    CME information and select publications here.

    Show More Show Less
    19 mins